Europeiska unionen - svenska - EMA (European Medicines Agency)

chiesi farmaceutici spa - koffein citrate - apné - psychoanaleptics, - behandling av primär apné hos prematura nyfödda.

Europeiska unionen - svenska - EMA (European Medicines Agency)

gilead sciences ireland uc, galapagos nv - filgotinib maleate - artrit, reumatoid - immunsuppressiva - rheumatoid arthritisjyseleca is indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease modifying anti rheumatic drugs (dmards). jyseleca may be used as monotherapy or in combination with methotrexate (mtx). ulcerative colitisjyseleca is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic agent.

Europeiska unionen - svenska - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - trastuzumab deruxtecan - bröst-neoplasmer - antineoplastiska medel - breast cancerher2-positive breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-positive breast cancer who have received one or more prior anti-her2-based regimens. her2-low breast cancerenhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic her2-low breast cancer who have received prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy (see section 4. non-small cell lung cancer (nsclc)enhertu as monotherapy is indicated for the treatment of adult patients with advanced nsclc whose tumours have an activating her2 (erbb2) mutation and who require systemic therapy following platinum-based chemotherapy with or without immunotherapy. gastric cancerenhertu as monotherapy is indicated for the treatment of adult patients with advanced her2-positive gastric or gastroesophageal junction (gej) adenocarcinoma who have received a prior trastuzumab-based regimen.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

meda ab - acetylsalicylsyra - tablett - 500 mg - acetylsalicylsyra 500 mg aktiv substans

Europeiska unionen - svenska - EMA (European Medicines Agency)

laboratorios lesvi s.l. - dimetylfumarat - multipel skleros, skovvis förlöpande - immunsuppressiva - dimethyl fumarate neuraxpharma is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis.

Europeiska unionen - svenska - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.

Europeiska unionen - svenska - EMA (European Medicines Agency)

akebia europe limited - vadadustat - renal insufficiency, chronic; anemia - antianemiska preparat - vafseo is indicated for the treatment of symptomatic anaemia associated with chronic kidney disease (ckd) in adults on chronic maintenance dialysis.

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

aristo pharma gmbh - paroxetinhydrokloridhemihydrat - filmdragerad tablett - 20 mg - paroxetinhydrokloridhemihydrat 22,2 mg aktiv substans; laktosmonohydrat hjälpämne - paroxetin

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

aristo pharma gmbh - abirateronacetat - filmdragerad tablett - 500 mg - abirateronacetat 500 mg aktiv substans; laktosmonohydrat hjälpämne; natriumlaurilsulfat hjälpämne

Sverige - svenska - Läkemedelsverket (Medical Products Agency)

aristo pharma gmbh - abirateronacetat - tablett - 250 mg - natriumlaurilsulfat hjälpämne; laktosmonohydrat hjälpämne; abirateronacetat 250 mg aktiv substans